Medistim ASA (FRA:MD1) Total Stockholders Equity: €37.23 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:MD1 Medistim ASA FRA:MD1
99 GF Score
Price €23.10
GF Value €23.94
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Medistim ASA Total Stockholders Equity?

Medistim ASA FRA:MD1 -0.43% 99 Total Stockholders Equity is €37.23 Mil as of Jun. 2026. GuruFocus rates FRA:MD1 with a GF Score™ of 99/100 and a GF Value™ of €23.94 (Fairly Valued). The stock has 4 warning signs investors should review.

Medistim ASA's Total Stockholders Equity for the quarter that ended in Jun. 2026 was €37.23 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Medistim ASA's Book Value per Share for the quarter that ended in Jun. 2026 was €2.04. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Medistim ASA's Debt-to-Equity for the quarter that ended in Jun. 2026 was 0.08.

Medistim ASA  (FRA:MD1) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Medistim ASA's Book Value per Share for the quarter that ended in Jun. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(37.229-0)/18.283
=2.04

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Medistim ASA's Debt-to-Equity for the quarter that ended in Jun. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 3.151) / 37.229
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medistim ASA Total Stockholders Equity Related Terms

Medistim ASA Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Medistim ASA's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medistim ASA Total Stockholders Equity Chart

Medistim ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 30.16 35.13 34.59 37.16 39.58

Medistim ASA Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 33.10 35.87 39.58 45.38 37.23
FRA:MD1
99GF Score
Medistim ASA FRA:MD1
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of €37.23 Mil mean?
Medistim ASA (FRA:MD1) has a Total Stockholders Equity of €37.23 Mil as of Jun. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Medistim ASA and its competitors.
Is Medistim ASA's Total Stockholders Equity too high?
Medistim ASA's current Total Stockholders Equity is €37.23 Mil. Overall, Medistim ASA has a GF Score™ of 99/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Medistim ASA's Total Stockholders Equity compare to ABT and SYK?
Medistim ASA's Total Stockholders Equity of €37.23 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Medical Devices & Instruments company?
A good Total Stockholders Equity depends on the Medical Devices & Instruments industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Medistim ASA and its competitors. Medistim ASA's current Total Stockholders Equity is €37.23 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medistim ASA stock overvalued right now?
Based on GuruFocus' analysis, Medistim ASA (FRA:MD1) is currently considered Fairly Valued. The stock's GF Value™ is €23.94, compared to a current price of €23.10 — trading 3.5% below its estimated fair value. The current Total Stockholders Equity is €37.23 Mil. Medistim ASA's overall GF Score™ is 99/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Medistim ASA (FRA:MD1), the current Total Stockholders Equity is €37.23 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medistim ASA (FRA:MD1) Overvalued in 2026?

Based on GuruFocus' analysis, Medistim ASA stock appears to be undervalued. The current stock price of €23.10 is trading 3.5% below its estimated GF Value™ of €23.94. GuruFocus considers Medistim ASA to be Fairly Valued.

Key valuation signals for FRA:MD1:

  • Total Stockholders Equity: €37.23 Mil
  • GF Value™: €23.94 vs. price of €23.10 (3.5% below fair value)
  • GF Score™: 99/100 with 4 warning signs

No single metric tells the full story. See the FRA:MD1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medistim ASA Business Description

Address Okernveien 94, Oslo, NOR, 0579
Medistim ASA is a medical device company. It is engaged in researching, developing, producing, distributing, and sales of medical equipment through its own business or participation in other companies, as well as related activities. The company's business is focused on cardiac and vascular surgery. The group operates in the USA, Europe, China, and the Rest of the World. The main divisions are sale of own products and sale of third-party products. Sale of own products has two business models, the capital model and the lease model. Third-party products segment sells medical devices from third party manufacturers in Norway, Sweden and Denmark. Key revenue is generated from Own Products segment.
99GF Score

Get the complete analysis for FRA:MD1

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€23.10
Price
€23.94
GF Value